Posted by Michael Wonder on 06 Dec 2022
Ionis announces European Medicines Agency accepts marketing authorisation application of tofersen to treat rare, genetic form of ALS
5 December 2022 - EMA acceptance follows FDA's acceptance of tofersen new drug application earlier this year.
Ionis Pharmaceuticals today announced that the EMA has accepted the marketing authorisation application for review of tofersen, an investigational medicine for the treatment of superoxide dismutase 1 amyotrophic lateral sclerosis.
